Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective-Reference-Cited by-同舟云学术

Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective

Published:2020-06-11 Issue:7 Volume:20 Page:823-827
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Connock Martin¹,Andronis Lazaros¹,Auguste Peter¹,Dussart Claude²^ORCID,Armoiry Xavier¹³

Affiliation:

1. Warwick Medical School, Faculty of Science Engineering and Medicine, University of Warwick, Coventry, UK

2. School of Pharmacy (ISPB)/EA P2S/Pharmacy Department, University of Lyon, Lyon, France

3. School of Pharmacy (ISPB)/UMR CNRS 5510 MATEIS/Edouard Herriot Hospital, Pharmacy Department, University of Lyon, Lyon, France

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1772747

Reference43 articles.

1. Drugs for exceptionally rare diseases: do they deserve special status for funding?

2. Quantifying emerging drugs for very rare conditions

3. Assessing the economic challenges posed by orphan drugs: A comment on Drummond et al.

4. Assessing the economic challenges posed by orphan drugs

5. UK-Gov. How UK orphan medicinal products will be managed in a no deal scenario; 2019 [cited 2020 May 29]. Available from: https://www.gov.uk/guidance/how-uk-orphan-medicinal-products-will-be-managed-in-a-no-deal-scenario

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal;Expert Review of Pharmacoeconomics & Outcomes Research;2023-04-19

2. Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives;Journal of Neuromuscular Diseases;2022-11-08

3. Critical Reflections on Reimbursement and Access of Advanced Therapies;Frontiers in Pharmacology;2022-05-18

4. Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy;Advances in Therapy;2022-03-20

5. Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA);PharmacoEconomics;2021-10-18